- Home
- EFSI vs RAPT Comparison
EFSI vs RAPT Comparison
Compare EFSI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSI
- RAPT
- Stock Information
- Founded
- EFSI 1881
- RAPT 2015
- Country
- EFSI United States
- RAPT United States
- Employees
- EFSI N/A
- RAPT N/A
- Industry
- EFSI Major Banks
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- EFSI Finance
- RAPT Health Care
- Exchange
- EFSI Nasdaq
- RAPT Nasdaq
- Market Cap
- EFSI 180.1M
- RAPT 194.2M
- IPO Year
- EFSI N/A
- RAPT 2019
- Fundamental
- Price
- EFSI $36.12
- RAPT $11.32
- Analyst Decision
- EFSI Strong Buy
- RAPT Buy
- Analyst Count
- EFSI 2
- RAPT 5
- Target Price
- EFSI $39.50
- RAPT $33.60
- AVG Volume (30 Days)
- EFSI 14.7K
- RAPT 103.2K
- Earning Date
- EFSI 07-24-2025
- RAPT 08-07-2025
- Dividend Yield
- EFSI 3.55%
- RAPT N/A
- EPS Growth
- EFSI N/A
- RAPT N/A
- EPS
- EFSI 1.85
- RAPT N/A
- Revenue
- EFSI $61,734,000.00
- RAPT N/A
- Revenue This Year
- EFSI $11.86
- RAPT N/A
- Revenue Next Year
- EFSI $12.83
- RAPT N/A
- P/E Ratio
- EFSI $19.48
- RAPT N/A
- Revenue Growth
- EFSI N/A
- RAPT N/A
- 52 Week Low
- EFSI $28.70
- RAPT $5.67
- 52 Week High
- EFSI $36.93
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- EFSI 79.03
- RAPT 54.68
- Support Level
- EFSI $34.76
- RAPT $10.06
- Resistance Level
- EFSI $35.42
- RAPT $12.25
- Average True Range (ATR)
- EFSI 0.60
- RAPT 1.02
- MACD
- EFSI 0.16
- RAPT -0.05
- Stochastic Oscillator
- EFSI 92.49
- RAPT 73.29
About EFSI Eagle Financial Services Inc Common Stock
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.